Long-standing, persistent shortages account for more than 90% of all drug shortages in the United States, according to the latest USP Annual Drug Shortages Report. Current shortages now last more than 4 years, up from about 3 years in 2023
APhA staff
Findings from a study published May 3, 2025, in The Lancet demonstrate that oral gepotidacin is a noninferior and safe alternative to ceftriaxone plus azithromycin for uncomplicated urogenital gonorrhea.
Dismissing patient, family, and caregiver concerns is the biggest threat to patient safety, according to ECRI. The organization said that time and resource constraints are making it increasingly difficult for health care providers to address patient concerns.
Preliminary data suggest that CDC’s recommendation that all qualified persons 6 months and older receive a 2024–2025 COVID-19 vaccination was an effective move.
On February 4, 2025, FDA approved Onapgo (apomorphine hydrochloride), a wearable infusion device, available soon in the United States for adults with advanced Parkinson’s disease.